A United Kingdom nationally representative survey of public attitudes towards pharmacogenomics

作者：Emma Magavern, Gabriel Marengo, Participant Panel at Genomics England, Chujan Sivathasan, Marta Mezzanzanica, Alison J. Wright, Jessica Keen, Videha Sharma, John McDermott, Claire Duckett, Dave McCormick, Shelley Simmonds, Emma Walters, John Weinman, Vivienne Parry, William G Newman, Mark J. Caulfield · 发表于：QJM · 年份：2025 · DOI：10.1093/qjmed/hcaf035 · 被引用次数：6 · 研究领域：Pharmacogenetics and Drug Metabolism、BRCA gene mutations in cancer、Genomics and Rare Diseases

BACKGROUND: Variation in DNA is known to contribute to medication response, impacting both medicine effectiveness and incidence of adverse drug reactions (ADRs). However, clinical implementation of pharmacogenomics (PGx) has been slow, and the views of the public are not well understood. AIM: To assess UK national public attitudes around pharmacogenetics. DESIGN AND METHODS: The survey was co-designed with the Participant Panel at Genomics England and the data were collected by the National Centre for Social Research, using its nationally representative panel of UK adults. Multivariable logistic regression analyses were used to analyse relationships between selected survey reported variables, controlled for age and sex. RESULTS: The survey response rate was 58%. Two thousand seven hundred and nineteen responses were obtained. Most respondents (59%) had experienced either no benefit or a side effect. Forty-five per cent of respondents reported having experienced no benefit and 46% of respondents reported having experienced a side effect, with female respondents more likely to be in both groups (P < 0.0001). Despite variability in interindividual medicine response being well understood (89%), the involvement of DNA in predicting benefit or risk of a side effect is not (understood by 52% and 48%, respectively). Eighty-nine per cent would complete a PGx test, with 91% wanting direct access to this information. Eighty-five per cent of UK adults think that the NHS should offer PGx ...